Personalized Cancer Treatment Illustration: Chemotherapy drugs flowing through a tree within a woman's silhouette, representing personalized medicine.

Unlocking the Link Between Body Composition and Chemotherapy Success

Samir D’Costa in Health & Wellness November 2025 • 4 min read.

"Discover how fat mass and lean mass impact treatment outcomes in breast cancer patients undergoing chemotherapy"

Chemotherapy, a cornerstone in the fight against breast cancer, often involves a combination of powerful drugs like anthracyclines and taxanes. While these treatments target cancer cells, they can also trigger a range of side effects, sometimes severe enough to warrant dose reductions, delays, or even premature termination of treatment. These modifications can compromise the treatment's effectiveness and impact long-term outcomes.

Currently, chemotherapy dosages are primarily calculated based on body surface area, a measure derived from height and weight. However, this method fails to account for the critical differences in body composition, specifically the ratio of lean mass to fat mass. Emerging research suggests that body composition plays a far more significant role in treatment response and toxicity than previously understood.

A new study published in Breast Cancer Research and Treatment delves into the intricate relationship between body composition and chemotherapy outcomes in women with stage I-IIIB breast cancer. This research sheds light on how fat mass and lean mass can influence the risk of toxicity-induced modifications of treatment, paving the way for more personalized and effective cancer care.

How Does Body Composition Affect Chemotherapy?

Personalized Cancer Treatment Illustration: Chemotherapy drugs flowing through a tree within a woman's silhouette, representing personalized medicine.

The study, conducted in the Netherlands, involved 172 breast cancer patients undergoing chemotherapy. Researchers used dual-energy X-ray absorptiometry (DEXA) scans to precisely measure each patient's body composition, including fat mass (both absolute and relative to total body weight) and lean mass (also absolute and relative). They then meticulously tracked toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy.

The results revealed a striking correlation: higher absolute and relative fat mass were associated with a significantly higher risk of treatment modifications. Specifically, for every 5 kg increase in fat mass, the risk of needing a modification increased by 14%. Similarly, a 5% increase in relative fat mass bumped up the risk by 21%. Conversely, a higher relative lean mass was linked to a lower risk of modifications. For every 5% increase in relative lean mass, the risk dropped by 17%. Absolute lean mass, however, did not show a significant association with treatment modifications.

Fat Mass: Higher fat mass increases toxicity risk.
Lean Mass: Higher relative lean mass decreases toxicity risk.
Dosage Calculation: Current methods may not be optimal.

These findings strongly suggest that fat mass plays a crucial role in determining how well a patient tolerates chemotherapy. While the study didn't pinpoint the exact mechanisms behind this association, several possibilities exist. Fat tissue may alter the way chemotherapy drugs are distributed and metabolized in the body, potentially leading to increased toxicity. Additionally, higher fat mass is often associated with chronic inflammation and other metabolic disturbances that could exacerbate chemotherapy side effects.

What This Means for You

The implications of this study are significant. It highlights the need to move beyond simplistic measures like body surface area and consider body composition when planning chemotherapy regimens. By accurately assessing a patient's fat mass and lean mass, oncologists can potentially personalize treatment strategies to minimize toxicity and maximize effectiveness. This may involve adjusting drug dosages, incorporating targeted nutritional interventions, or implementing exercise programs to improve body composition during treatment.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1007/s10549-018-5014-5, Alternate LINK

Title: Body Composition Is Associated With Risk Of Toxicity-Induced Modifications Of Treatment In Women With Stage I–Iiib Breast Cancer Receiving Chemotherapy

Subject: Cancer Research

Journal: Breast Cancer Research and Treatment

Publisher: Springer Science and Business Media LLC

Authors: Maaike M. G. A. Van Den Berg, Dieuwertje E. Kok, Liesbeth Posthuma, Lisette Kamps, Celine S. Kelfkens, Nicole Buist, Maud Geenen, Annebeth Haringhuizen, Joan B. Heijns, Rianne H. M. A. Van Lieshout, Maartje Los, Dirkje W. Sommeijer, Johanna N. H. Timmer-Bonte, Anja Th. C. M. De Kruif, Hanneke W. M. Van Laarhoven, Ellen Kampman, Renate M. Winkels

Published: 2018-10-23

Everything You Need To Know

How does body composition impact the effectiveness of chemotherapy treatments, specifically those using anthracyclines and taxanes, for breast cancer patients?

Body composition, particularly the ratio of fat mass to lean mass, significantly influences how breast cancer patients respond to chemotherapy involving drugs like anthracyclines and taxanes. Higher fat mass is associated with increased risk of toxicity-induced modifications such as dose reductions or delays, while higher relative lean mass is linked to a lower risk of such modifications. Current methods using body surface area for dosage calculation do not account for these critical differences, potentially affecting treatment outcomes.

What specific types of body composition measurements are most relevant for predicting chemotherapy outcomes in breast cancer?

The most relevant body composition measurements for predicting chemotherapy outcomes are fat mass (both absolute and relative to total body weight) and lean mass (relative to total body weight). Studies show that higher absolute and relative fat mass increase the risk of toxicity-induced treatment modifications, while higher relative lean mass reduces this risk. Absolute lean mass did not show a significant association with treatment modifications, indicating that relative lean mass is more indicative.

How are dual-energy X-ray absorptiometry (DEXA) scans used to assess body composition in breast cancer patients undergoing chemotherapy, and what specific information do they provide?

Dual-energy X-ray absorptiometry (DEXA) scans are used to precisely measure a patient's body composition, including fat mass and lean mass. The DEXA scan provides quantitative data on both absolute and relative fat mass, as well as absolute and relative lean mass. This detailed information allows researchers and clinicians to understand the distribution of fat and muscle in the body, which is crucial for predicting chemotherapy outcomes and personalizing treatment strategies. It's more comprehensive than standard height and weight measurements because it distinguishes between fat and muscle.

Why does higher fat mass increase the risk of chemotherapy toxicity, and what are the potential mechanisms behind this association?

Higher fat mass is associated with an increased risk of chemotherapy toxicity due to several potential mechanisms. Fat tissue may alter the distribution and metabolism of chemotherapy drugs, potentially leading to increased toxicity. Additionally, higher fat mass is often linked to chronic inflammation and metabolic disturbances, which can exacerbate chemotherapy side effects. Understanding these mechanisms is crucial for developing targeted interventions to mitigate toxicity and improve treatment outcomes.

Given the impact of body composition on chemotherapy outcomes, what personalized strategies can oncologists implement to improve treatment effectiveness and reduce toxicity in breast cancer patients?

Considering the influence of body composition, oncologists can adopt personalized strategies such as adjusting chemotherapy drug dosages based on fat mass and lean mass. They can also incorporate targeted nutritional interventions to manage body composition during treatment. Furthermore, implementing exercise programs designed to improve lean mass and reduce fat mass can be beneficial. These strategies aim to minimize toxicity, maximize treatment effectiveness, and improve the overall outcomes for breast cancer patients undergoing chemotherapy, especially treatments involving anthracyclines and taxanes.